Qiagen NV (LTS:0RLT)
€ 43.54 0 (0%) Market Cap: 9.70 Bil Enterprise Value: 10.12 Bil PE Ratio: 113.19 PB Ratio: 2.90 GF Score: 82/100

Qiagen NV at Goldman Sachs Healthcare Conference Transcript

Jun 13, 2023 / 04:20PM GMT
Release Date Price: €44.02 (+0.67%)
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst

All right. Welcome, everybody. Good morning. I'm Matt Sykes, the Life Sciences Tools and Diagnostics analyst at Goldman Sachs. And I have a pleasure to welcome Thierry Bernard, the CEO of QIAGEN here today. Thierry, thank you very much for being here.

Thierry Bernard
Qiagen N.V. - CEO, MD & Member of Management Board

Thanks for having us.

Questions & Answers

Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst

And maybe why don't we just start out, let you kind of set the stage a little bit. Last quarter, you once again exceeded expectations for net sales growth and EPS in the quarter. Maybe walk us through some of the key accomplishments and any expectations you have over the course of this year?

Thierry Bernard
Qiagen N.V. - CEO, MD & Member of Management Board

So first of all, good morning, everybody, and thanks for your

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot